
Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.920 | 3.960 | 3.040 |
Shares | 99.080 | 99.080 | 0.000 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 26.756 | 29.513 |
Price to Book | - | 3.619 |
Price to Sales | 3.517 | 4.684 |
Price to Cash Flow | 16.069 | 19.097 |
Dividend Yield | 0.463 | 0.781 |
5 Years Earnings Growth | 22.637 | 17.188 |
Name | Net % | Category Average |
---|---|---|
Healthcare | 81.510 | 95.841 |
Energy | 6.920 | 6.920 |
Consumer Defensive | 5.950 | 5.950 |
Technology | 5.620 | 5.620 |
Number of long holdings: 19
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Divi's Labs | INE361B01024 | 9.67 | 5,258.95 | -4.08% | |
RPG Life Sciences Limited | INE105J01010 | 9.05 | 1,993.90 | -8.36% | |
Aster DM Healthcare | INE914M01019 | 8.18 | 475.80 | -1.39% | |
Zydus Lifesciences | INE010B01027 | 7.39 | 837.60 | -3.38% | |
Ipca Laboratories | INE571A01038 | 7.13 | 1,301.05 | -7.02% | |
Torrent Pharma | INE685A01028 | 7.11 | 3,233.55 | -1.61% | |
Reliance Industries | INE002A01018 | 6.71 | 1,165.70 | -3.24% | |
Aurobindo Pharma | INE406A01037 | 6.62 | 1,094.05 | -1.02% | |
Alivus Life Sciences | INE03Q201024 | 6.27 | 973.15 | -2.79% | |
Zydus Wellness | INE768C01010 | 5.77 | 1,682.00 | -0.90% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
INF966L01689 | 228.32B | -17.06 | 21.72 | 18.72 | ||
INF966L01051 | 228.32B | -17.19 | 20.32 | 17.88 | ||
Quant Mid Cap Fund Growth | 76.16B | -14.99 | 18.20 | 15.54 | ||
INF966L01887 | 76.16B | -14.83 | 20.05 | 16.76 | ||
Quant Consumption Fund Growth | 61.89B | -12.49 | 16.01 | 16.93 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review